Project description:RNA-seq samples in SCCOHT-1 and COV434 for idasanutlin treatment (0.5μM, 24h), and RNA-seq samples in BIN-67 and COV434 for short-term idasanutlin treatment (0.5μM, 3h). The goal of the experiment is to assess the genes that are regulated by p53 stabilization in the long term or short term using idasanutlin treatment in SCCOHT.
Project description:To examine the role SMARCA4-p53 regulatory axis in SCCOHT cells we performed RNA-seq in BIN-67 cells with SMARCA4 restoration, p53ko alone or combined with SMARCA4 and idasanutlin treatment (0.5μM, 24h) which increase the stability of p53 and its protein levels in SCCOHT.
Project description:RNA-seq samples in BIN-67 and BIN-67p53-ko cells with or without A-485 treatment (1μM, 24h). The goal of the experiment is to assess the genes that are regulated by p300 acetyltransferase inhibition using A-485 treatment and weather p53-ko can rescue this phenotype.
Project description:Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in SMARCA4 (BRG1), one of the two mutually exclusive ATPases of the SWI/SNF chromatin remodeling complex. To address the role that BRG1 loss plays in SCCOHT tumorigenesis, we performed integrative multi-omic analyses in SCCOHT cell lines +/- BRG1 re-expression. BRG1 re-expression induced a gene and protein signature similar to an epithelial cell and gained chromatin accessibility sites correlated with other epithelial originating TCGA tumors. Furthermore, AP-1 motifs were enriched at the promoters of highly upregulated epithelial genes. Using a dominant negative AP-1 cell line, we found that both AP-1 DNA binding activity and BRG1 re-expression are necessary for the gene and protein expression of epithelial genes. Our study demonstrates that BRG1 re-expression drives an epithelial-like gene and protein signature in SCCOHT cells that depends upon AP-1 activity.
Project description:Transcriptional profiling of 2 SCCOHT patient-derived xenograft (PDX) models and 2 SCCOHT cell lines compared to normal ovary to investigate underlying biology of SCCOHT. RNA from 2 SCCOHT PDXs and 2 SCCOHT cell lines were individually hybridized with a pool of 2 commercial normal ovary RNA on Agilent whole human genome 4x44K microarrays.
Project description:Transcriptional profiling of 2 SCCOHT patient-derived xenograft (PDX) models and 2 SCCOHT cell lines compared to normal ovary to investigate underlying biology of SCCOHT.
Project description:ChIP-seq was performed in BIN-67, BIN-67 p53ko, BIN-67 with SMARCA4 restoration and BIN-67 p53ko cells with SMARCA4 restoration to assess the impact of SMARCA4 and p53 on the pull downs of p300, H3K27ac, p53, HDAC1 and HDAC2.
Project description:Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare form of ovarian cancer that has not previously been characterized at the gene expression level. The goal of this study was to generate gene expression profiles from SCCOHT tumor samples by RNA-Seq.
Project description:Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in SMARCA4 (BRG1), one of the two mutually exclusive ATPases of the SWI/SNF chromatin remodeling complex. To address the role that SMARCA4 loss plays in SCCOHT tumorigenesis, we performed RNA-seq in a SCCOHT cell line +/- SMARCA4 re-expression. SMARCA4 re-expression was acheived by integration of pIND20-BRG1 and inducing with doxycycline. The goal of this study was to generate a high sequencing depth RNA-seq dataset to determine how restoration of SMARCA4 results in changes in gene expression and RNA splicing.